Nuvation Bio (1E30) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
1E30 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Nuvation Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.17 |
| 52 Week High | US$6.66 |
| 52 Week Low | US$4.50 |
| Beta | 1.52 |
| 1 Month Change | 6.57% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 37.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1E30 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 13.1% | -0.09% | -0.8% |
| 1Y | n/a | 41.2% | 2.4% |
Return vs Industry: Insufficient data to determine how 1E30 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 1E30 performed against the German Market.
Price Volatility
| 1E30 volatility | |
|---|---|
| 1E30 Average Weekly Movement | 16.7% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 1E30's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 1E30's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 305 | David Hung | www.nuvationbio.com |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo.
Nuvation Bio Inc. Fundamentals Summary
| 1E30 fundamental statistics | |
|---|---|
| Market cap | €2.18b |
| Earnings (TTM) | -€128.31m |
| Revenue (TTM) | €145.50m |
Is 1E30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1E30 income statement (TTM) | |
|---|---|
| Revenue | US$169.90m |
| Cost of Revenue | US$20.09m |
| Gross Profit | US$149.81m |
| Other Expenses | US$299.64m |
| Earnings | -US$149.83m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 88.18% |
| Net Profit Margin | -88.19% |
| Debt/Equity Ratio | 162.5% |
How did 1E30 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/20 13:11 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nuvation Bio Inc. is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |